Published Date: 02 Mar 2023
A deep learning model called Sybil can predict future lung cancer risk based on a low-dose chest CT scan and identify people who are likely to benefit from regular treatment.
Read Full NewsSusan Corbridge, PhD, and Alanna Kavannagh, MSN, CCRN, discuss the role of advanced practice providers on the evolving pulmonary and critical care teams during CHEST 2025.
The phase 3 study aims to confirm findings from the HEALEY ALS platform trial in patients with early-stage rapidly progressive ALS, which suggested potential benefits of pridopidine across multiple domains.
Holzem spoke in this interview about several additional highlights from her session at SDPA Fall regarding red flags in dermatology and when to admit from the clinic.
Key Skin Cancer Terms Not Understood by Almost 1/3 of Patients Surveyed
1.
high response rate when using a bispecific antibody to treat R/R multiple myeloma.
2.
Imetelstat for MDS-relateret anemia er godkendt af Food and Drug Administrations panel.
3.
New research uncovers link between cancer pathway and blood-retina barrier function
4.
Alternative breast imaging techniques beyond mammography.
5.
FAPI PET/CT enhances the staging of recently discovered breast cancer, according to comparative analysis.
1.
Exploring The Causes and Consequences of Low Transferrin Saturation
2.
Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors
3.
What is Red Cell Distribution Width and Why Should You Care?
4.
Uncovering the Hidden Symptoms of Parathyroid Cancer in Women
5.
The importance of understanding normal serum osmolality
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Virtual Case Study on Deep Vein Thrombosis (DVT) - An Initiative by Hidoc Dr.
2.
Navigating the Complexities of Ph Negative ALL - Part X
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
4.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
5.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation